Medpace Holdings Inc

MEDP remains in a Stage 2 advancing regime with a clear sequence of higher highs and higher lows supported by rising EMAs and healthy volume patterns. Recent overbought conditions and minor exhaustion signals near resistance have led to a pullback into the 9 EMA and 21 EMA, where price is currently holding. While the medium‐term bullish bias stays intact under the Stage 2 framework and active HH/HL pattern, execution is deferred until a stronger acceptance at moving average support rather than initiating now.

• ↑Q1 2026 revenue $706.6M (+26.5% YoY); backlog expected to convert ~$1.9B next 12 months
• ↑Backlog at $2.93B underpins revenue visibility through FY27
• ↓Q4 cancellations highest in over a year, yielding 0.88 net book-to-bill